Feb 4, 2026 07:31AM Zevra presents four-year MIPLYFFA data for rare disease treatment

Dec 30, 2025 06:38AM H.C. Wainwright Reiterates Buy Rating on Zevra Therapeutics, Inc. (ZVRA)

Dec 29, 2025 07:30AM Zevra partners with Uniphar to expand access to rare disease therapy

Dec 2, 2025 07:37AM Zevra Therapeutics appoints Alicia Secor to board following Dixon resignation

Nov 20, 2025 04:32PM Zevra Therapeutics (ZVRA) announces CFO Resignation

Nov 5, 2025 04:51PM Zevra Therapeutics, Inc. (ZVRA) Tops Q2 EPS by 2c

Oct 17, 2025 07:21AM Cantor Fitzgerald Reiterates Overweight Rating on Zevra Therapeutics, Inc. (ZVRA): Notes Patent Potential

Sep 19, 2025 05:59AM Increasing unusual option volume: EWC CDLX ZVRA HPP UP BFLY LDI CBRL

Aug 21, 2025 10:39AM Zevra Therapeutics (ZVRA) Strength Tied to Unconfirmed Market Chatter

Aug 13, 2025 04:08AM Zevra Therapeutics, Inc. (ZVRA) PT Lowered to $18 at Citizens JMP

Aug 12, 2025 04:07PM Zevra Therapeutics, Inc. (ZVRA) Misses Q1 EPS by $2.25

Jul 10, 2025 07:17AM Zevra Therapeutics, Inc. (ZVRA) PT Raised to $29 at Cantor Fitzgerald

Jul 2, 2025 06:37AM H.C. Wainwright Assumes Zevra Therapeutics, Inc. (ZVRA) at Buy

May 29, 2025 04:36PM Zevra Therapeutics (ZVRA) announces AGM results

May 14, 2025 06:33AM Zevra Therapeutics, Inc. (ZVRA) Tops Q1 EPS by 18c

Apr 21, 2025 07:22AM Zevra Therapeutics (ZVRA) Files Definitive Proxy Statement and Mails Letter to Stockholders

Mar 31, 2025 04:12PM Zevra Therapeutics (ZVRA) Files Preliminary Proxy

Mar 13, 2025 06:57AM Zevra Therapeutics, Inc. (ZVRA) PT Raised to $25 at Canaccord Genuity

Mar 12, 2025 06:55AM Cantor Fitzgerald Reiterates Overweight Rating on Zevra Therapeutics, Inc. (ZVRA)

Mar 12, 2025 06:27AM Zevra Therapeutics, Inc. (ZVRA) PT Raised to $18 at Citizens JMP

Mar 11, 2025 04:21PM Zevra Therapeutics, Inc. (ZVRA) Misses Q4 EPS by 27c

Feb 27, 2025 07:37AM Zevra Therapeutics (ZVRA) Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Feb 3, 2025 03:21PM Zevra Therapeutics (ZVRA) 900 contracts of August 7 puts trade at $1.10

Feb 3, 2025 04:43AM JMP Securities Biotechnology Overview

Nov 21, 2024 04:53PM Zevra Therapeutics (ZVRA) Announces U.S. Commercial Availability of MIPLYFFA (arimoclomol) for Treatment of Niemann-Pick Disease Type C

Nov 12, 2024 04:28PM Zevra Therapeutics, Inc. (ZVRA) Misses Q3 EPS by 28c

Nov 11, 2024 04:40PM Zevra Therapeutics (ZVRA) to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale

Sep 30, 2024 07:26AM H.C. Wainwright Reiterates Buy Rating on Zevra Therapeutics, Inc. (ZVRA)

Sep 24, 2024 07:56AM Zevra Therapeutics, Inc. (ZVRA) PT Raised to $25 at Maxim Group

Sep 24, 2024 05:40AM Zevra Therapeutics, Inc. (ZVRA) PT Raised to $21 at Roth/MKM

Sep 24, 2024 02:37AM JMP Securities Starts Zevra Therapeutics, Inc. (ZVRA) at Market Outperform

Sep 23, 2024 06:35AM Zevra Therapeutics, Inc. (ZVRA) PT Raised to $20 at H.C. Wainwright

Sep 20, 2024 12:08PM Zevra Therapeutics' (ZVRA) MIPLYFFA Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

Sep 20, 2024 09:49AM Zevra Therapeutics (ZVRA) Halted, News Pending

Sep 20, 2024 09:49AM Zevra Therapeutics (ZVRA) Denmark Gets FDA Approval For NDA For Miplyffa

Sep 18, 2024 07:24AM Zevra Therapeutics, Inc. (ZVRA) PT Lowered to $22 at Canaccord Genuity

Sep 6, 2024 10:14AM Roth/MKM Reiterates Buy Rating on Zevra Therapeutics, Inc. (ZVRA)

Aug 13, 2024 05:02PM Zevra Therapeutics, Inc. (ZVRA) Misses Q2 EPS by 2c

Aug 9, 2024 06:20AM Zevra Therapeutics (ZVRA) Prices 9.23M Share Offering at $6.50/sh

Aug 8, 2024 04:01PM Zevra Therapeutics (ZVRA) Announces Proposed Share Offering

Jul 10, 2024 08:29AM H.C. Wainwright Reiterates Buy Rating on Zevra Therapeutics, Inc. (ZVRA)

Jul 9, 2024 02:17PM William Blair Reiterates Outperform Rating on Zevra Therapeutics, Inc. (ZVRA)

Jul 9, 2024 09:06AM Zevra (ZVRA) Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Jun 10, 2024 12:24PM Cantor Fitzgerald Reiterates Overweight Rating on Zevra Therapeutics, Inc. (ZVRA)